Gastroenterology Research and Practice / 2015 / Article / Tab 2

Clinical Study

Hepatorenal Syndrome: Outcome of Response to Therapy and Predictors of Survival

Table 2

Univariate analysis of the patient cohort.

VariableResponseNo response value

HRS type 1/2, 47/1845/90.165
Ascites, grade 1/2/39/38/1811/25/160.466
Treatment, median days (IRQ) 9 6–1410.5 5–190.350
HE, grade 1/2/346/15/339/14/10.699
Serum protein, g/L5.84 ± 1.275.30 ± 1.470.040
INR 1.60 ± 0.521.64 ± 0.440.698
Serum sodium (mmol/L)133.60 ± 6.21133.12 ± 5.730.714
Serum potassium (mmol/L)4.34 ± 0.804.22 ± 0.710.381
Serum creatinine (mg/dL)2.79 ± 1.243.07 ± 1.470.207
Urea (mg/dL)55.30 ± 24.6867.47 ± 51.590.189
Bilirubin (mg/dL)8.12 ± 10.2310.59 ± 12.290.901
Terlipressin dose (mg)26.43 ± 30.8632.11 ± 31.570.450
Albumin dose (g)266.26 ± 236.31298.14 ± 252.020.612

HE: hepatic encephalopathy; INR: international normalized ratio.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.